Home   Drug Development   CRO Services   Newsroom   About ReceptoPharm   Contact
» Recent News
» Archives
» E-Alerts
Drug Development

ReceptoPharm is developing proprietary therapeutic protein products for the treatment of neurological, viral and and autoimmune disorders.

» Learn More
CRO Services

ReceptoPharm offers a full range of contract research services catering to small and start-up biotech companies.

» Learn More


Nutra Pharma Sponsors Educational Website for Adrenomyeloneuropathy (AMN)
January 16, 2007

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has sponsored, a website dedicated to educating patients and providing information about Adrenomyeloneuropathy (AMN).

“Although there is currently no approved treatment for AMN, we felt that it is important to educate patients about this disease and to provide information about current treatment research,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “The sponsorship of coincides with our progression into a Phase IIb human clinical trial for the treatment of AMN,” he added.

The website will feature information about Adrenomyeloneuropathy: its symptoms, diagnosis, treatment research, and links to regional, national, and international support groups.

“AMN is a rare inherited metabolic disorder, but still interests the wider neurologic community because of its similarities to Multiple Sclerosis,” commented Stewart Lonky, MD, a member of the board of directors of Nutra Pharma Corporation.“AMN is often misdiagnosed and confused with Multiple Sclerosis and it is our hope that the website will help educate the public about the differences between the two diseases,” he concluded.

RPI-78M is ReceptoPharm's lead drug candidate for the treatment of neurological and autoimmune disorders. The drug has already completed pre-clinical testing and a Phase I/IIa human trial in AMN. In October, ReceptoPharm received Ethics Committee approval in the UK to begin its Phase IIb human clinical trial for the treatment of AMN.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The sponsorship of should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

Recent News
November 05, 2010
Nutra Pharma Awarded Grant under the Qualifying Therapeutic Discovery Project Program
Signup to receive news and announcements from ReceptoPharm and Nutra Pharma:
First Name:
Last Name: